Which Imaging Modality Is Superior for Prediction of Response to Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer?
Table 2
Association of patient and tumor characteristics comparing residual disease versus no residual disease (pathologic complete response, pCR) following neoadjuvant chemotherapy in 148 patients with 151 triple negative breast cancers.
Characteristic (pretreatment)
Residual disease (%)
pCR (%)
P value
Age*
50
67 (61)
25 (66)
NS
≥50
43 (39)
13 (34)
Race*
Caucasian
66 (60)
20 (53)
African-American
41 (37)
16 (42)
NS
Other
3 (3)
2 (5)
Clinical T stage
T1
16 (14)
6 (16)
T2
51 (45)
22 (58)
NS
T3
37 (33)
10 (26)
Unknown
9 (8)
0 (0)
Nuclear grade
Grade 1
2 (2)
0 (0)
Grade 2
15 (13)
1 (3)
NS
Grade 3
90 (80)
35 (92)
Unknown
6 (5)
2 (5)
Clinical N status
N0
43 (39)
19 (50)
N1
48 (42)
15 (39)
N2
7 (6)
3 (8)
NS
N3
8 (7)
1 (3)
Unknown
7 (6)
0 (0)
Clinical Stage
1
6 (5)
4 (11)
2
58 (51)
25 (66)
NS
3
38 (34)
7 (18)
Unknown
11 (10)
2 (5)
Neoadjuvant regimen#
Taxane-based
96 (85)
36 (95)
NS
Nontaxane$
17 (15)
2 (5)
for patients characteristics (age, race). overall but includes 3 patients with two cancer cases—all 3 received taxane-based regimens.
$Nontaxane regimens included cisplatin- and epirubicin-based regimens.
